The Efficacy and Influencing Factors of Polymyxin B in High-Level Carbapenem-Resistant Klebsiella pneumoniae Infections

References

• Jean SS, Harnod D, Hsueh PR. Global threat of carbapenem-resistant gram-negative bacteria. Front Cell Infect Microbiol. 2022;12:823684. doi:10.3389/fcimb.2022.823684
   PubMed Web of Science ®Google Scholar
• Zhou R, Fang X, Zhang J, et al. Impact of carbapenem resistance on mortality in patients infected with Enterobacteriaceae: a systematic review and meta-analysis. BMJ Open. 2021;11(12):e054971. doi:10.1136/bmjopen-2021-054971
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Q, Yin Y, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae infections: report from the China CRE network. Antimicrob Agents Chemother. 2018;62(2). doi:10.1128/AAC.01882-17
   Web of Science ®Google Scholar
• Gao L, Lv Y, Li Y. Analysis of the drug resistance of carbapenem-resistant Klebsiella pneumoniae in the China antimicrobial resistance surveillance trial program, 2007–2018. Microb Drug Resist. 2020;26(8):944–950. doi:10.1089/mdr.2019.0299
   PubMed Web of Science ®Google Scholar
• Karampatakis T, Tsergouli K, Behzadi P. Carbapenem-Resistant Klebsiella pneumoniae: Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options. Antibiotics. 2023;12(2):234.
   Google Scholar
• Eisert A, Lanckohr C, Frey J, et al. Comparison of two empirical prolonged infusion dosing regimens for meropenem in patients with septic shock: a two-center pilot study. Int J Antimicrob Agents. 2021;57(3):106289. doi:10.1016/j.ijantimicag.2021.106289
   PubMed Web of Science ®Google Scholar
• Yu Z, Pang X, Wu X, Shan C, Jiang S, Miyamoto A. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis. PLoS One. 2018;13(7):e0201667. doi:10.1371/journal.pone.0201667
   PubMed Web of Science ®Google Scholar
• Zhao YC, Zou Y, Xiao YW, et al. Does prolonged infusion time really improve the efficacy of meropenem therapy? A prospective study in critically ill patients. Infect Dis Ther. 2022;11(1):201–216. doi:10.1007/s40121-021-00551-2
   PubMed Web of Science ®Google Scholar
• Bassetti M, Peghin M, Pecori D. The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2016;29(6):583–594. doi:10.1097/QCO.0000000000000314
   PubMed Web of Science ®Google Scholar
• Tompkins K, van Duin D. Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions. Eur J Clin Microbiol Infect Dis. 2021;40(10):2053–2068. doi:10.1007/s10096-021-04296-1
   PubMed Web of Science ®Google Scholar
• Tilahun M, Kassa Y, Gedefie A, Ashagire M. Emerging carbapenem-resistant Enterobacteriaceae infection, its epidemiology and novel treatment options: a review. Infect Drug Resist. 2021;14:4363–4374. doi:10.2147/IDR.S337611
   PubMed Web of Science ®Google Scholar
• Jia X, Guo C, Yin Z, Zhang W, Du S, Zhang X. Risk factors for acute kidney injury induced by intravenous polymyxin B in Chinese patients with severe infection. Infect Drug Resist. 2022;15:1957–1965. doi:10.2147/IDR.S363944
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Falci DR, Zavascki AP. Clinical use of polymyxin B. Adv Exp Med Biol. 2019;1145:197–218.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kyriakidou M, Voulgaris GL, Vokos F, Politi S, Kechagias KS. Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: an evaluation of the current evidence. J Global Antimicrob Resist. 2021;24:342–359. doi:10.1016/j.jgar.2020.12.026
   PubMed Web of Science ®Google Scholar
• Nang SC, Azad MAK, Velkov T, Zhou QT, Li J. Rescuing the last-line polymyxins: achievements and challenges. Pharmacol Rev. 2021;73(2):679–728. doi:10.1124/pharmrev.120.000020
   PubMed Web of Science ®Google Scholar
• Yan WJ, Jing N, Wang SM, et al. Molecular characterization of carbapenem-resistant Enterobacteriaceae and emergence of tigecycline non-susceptible strains in the Henan province in China: a multicentrer study. J Med Microbiol. 2021;70(3). doi:10.1099/jmm.0.001325
   Web of Science ®Google Scholar
• Shein AMS, Hongsing P, Abe S, et al. Will there ever be cure for chronic, life-changing colistin-resistant Klebsiella pneumoniae in urinary tract infection? Front Med. 2021;8:806849. doi:10.3389/fmed.2021.806849
   Web of Science ®Google Scholar
• Shein AMS, Wannigama DL, Higgins PG, et al. Novel colistin-EDTA combination for successful eradication of colistin-resistant Klebsiella pneumoniae catheter-related biofilm infections. Sci Rep. 2021;11(1):21676. doi:10.1038/s41598-021-01052-5
   PubMed Web of Science ®Google Scholar
• Shein AMS, Wannigama DL, Higgins PG, et al. High prevalence of mgrB-mediated colistin resistance among carbapenem-resistant Klebsiella pneumoniae is associated with biofilm formation, and can be overcome by colistin-EDTA combination therapy. Sci Rep. 2022;12(1):12939. doi:10.1038/s41598-022-17083-5
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Lewis JS, Weinstein MP, et al. Clinical and Laboratory Standards Institute and European Committee on antimicrobial susceptibility testing position statements on polymyxin B and colistin clinical breakpoints. Clin Infect Dis. 2020;71(9):e523–e529. doi:10.1093/cid/ciaa121
   PubMed Web of Science ®Google Scholar
• Venkataraman R, Kellum JA. Defining acute renal failure: the RIFLE criteria. J Intensive Care Med. 2007;22(4):187–193. doi:10.1177/0885066607299510
   PubMedGoogle Scholar
• Lu Q, Li GH, Qu Q, et al. Clinical efficacy of polymyxin B in patients infected with carbapenem-resistant organisms. Infect Drug Resist. 2021;14:1979–1988. doi:10.2147/IDR.S312708
   PubMed Web of Science ®Google Scholar
• Qu J, Qi TT, Qu Q, et al. Polymyxin B-based regimens for patients infected with carbapenem-resistant gram-negative bacteria: clinical and microbiological efficacy, mortality, and safety. Infect Drug Resist. 2022;15:1205–1218. doi:10.2147/IDR.S357746
   PubMed Web of Science ®Google Scholar
• Xia GL, Jiang RL. Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections. BMC Infect Dis. 2021;21(1):1034. doi:10.1186/s12879-021-06719-y
   PubMed Web of Science ®Google Scholar
• Zhang X, Qi S, Duan X, et al. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study. J Transl Med. 2021;19(1):431. doi:10.1186/s12967-021-03111-x
   PubMed Web of Science ®Google Scholar
• Chang K, Wang H, Zhao J, et al. Polymyxin B/Tigecycline Combination vs Polymyxin B or Tigecycline Alone for the treatment of hospital-acquired pneumonia caused by carbapenem-resistant Enterobacteriaceae or carbapenem-resistant Acinetobacter baumannii. Front Med. 2022;9:772372. doi:10.3389/fmed.2022.772372
   Web of Science ®Google Scholar
• Tian Y, Zhang Q, Wen L, Chen J, Van Tyne D. Combined effect of polymyxin B and tigecycline to overcome heteroresistance in carbapenem-resistant Klebsiella pneumoniae. Microbiol Spectr. 2021;9(2):e0015221. doi:10.1128/Spectrum.00152-21
   PubMed Web of Science ®Google Scholar
• Lu Q, Zhu HH, Li GH, et al. A comparative study of the microbiological efficacy of polymyxin B on different carbapenem-resistant gram-negative bacteria infections. Front Med. 2021;8:620885. doi:10.3389/fmed.2021.620885
   Web of Science ®Google Scholar
• Cai Y, Leck H, Tan RW, et al. Clinical experience with high-dose polymyxin B against carbapenem-resistant gram-negative bacterial infections-A cohort study. Antibiotics. 2020;9(8):451. doi:10.3390/antibiotics9080451
   Web of Science ®Google Scholar
• Liang Q, Huang M, Xu Z. Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Braz J Infect Dis. 2019;23(1):60–65. doi:10.1016/j.bjid.2018.12.004
   PubMed Web of Science ®Google Scholar
• Medeiros GS, Rigatto MH, Falci DR, Zavascki AP. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents. 2019;53(2):152–157. doi:10.1016/j.ijantimicag.2018.10.010
   PubMed Web of Science ®Google Scholar
• Jia X, Yin Z, Zhang W, Guo C, Du S, Zhang X. Effectiveness and nephrotoxicity of intravenous polymyxin B in carbapenem-resistant gram-negative bacterial infections among Chinese children. Front Pharmacol. 2022;13:902054. doi:10.3389/fphar.2022.902054
   PubMed Web of Science ®Google Scholar
• Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother. 2010;65(10):2231–2237. doi:10.1093/jac/dkq285
   PubMed Web of Science ®Google Scholar
• Wistrand-Yuen P, Olsson A, Skarp KP, et al. Evaluation of polymyxin B in combination with 13 other antibiotics against carbapenemase-producing Klebsiella pneumoniae in time-lapse microscopy and time-kill experiments. Clin Microbiol Infect. 2020;26(9):1214–1221. doi:10.1016/j.cmi.2020.03.007
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39. doi:10.1002/phar.2209
   PubMed Web of Science ®Google Scholar
• Hou SY, Wu D, Feng XH. Polymyxin monotherapy versus polymyxin-based combination therapy against carbapenem-resistant Klebsiella pneumoniae: a systematic review and meta-analysis. J Global Antimicrob Resist. 2020;23:197–202. doi:10.1016/j.jgar.2020.08.024
   PubMed Web of Science ®Google Scholar
• Teo JQ, Chang CW, Leck H, et al. Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: a case-control study. Int J Antimicrob Agents. 2019;53(5):657–662. doi:10.1016/j.ijantimicag.2019.03.011
   PubMed Web of Science ®Google Scholar
• Macesic N, Nelson B, McConville TH, et al. Emergence of polymyxin resistance in clinical Klebsiella pneumoniae through diverse genetic adaptations: a genomic, retrospective cohort study. Clin Infect Dis. 2020;70(10):2084–2091. doi:10.1093/cid/ciz623
   PubMed Web of Science ®Google Scholar